← Ecosystem map
FimmCyte AG
Biotechnology company developing targeted immunotherapies for chronic fibro-inflammatory diseases, with a lead candidate for endometriosis.
At a glance
- What it offers
- Biotech
- Primary health focus
- Endometriosis
- Who it supports
- Patients and Consumers, Healthcare Professionals
- Company stage
- Pilot / Validation
About
FimmCyte is conducting research and development on FMC2 with Gedeon Richter to move the candidate towards clinical testing. The agreement gives Richter an exclusive global option to license the therapy before the first-in-human trial.
Need addressed
Endometriosis
Organisation’s contribution
Founded in 2022 as a spin-off from the University of Zurich and University Hospital Zurich.
Women’s health focus
Women’s Health Core
Primary health area
EndometriosisProduct & development
- Clinical stage
- FMC2 is being advanced towards clinical testing; the March 2026 announcement places the first-in-human trial ahead of the programme.